SNCA and Parkinson disease: One class that is under consideration, but yet to enter clinical trials, is the β-adrenergic receptor agonists, given recent epidemiological andin vitro work demonstrating an association with reduced α-synuclein levels and risk of PD, thought to be mediated through modulation ofSNCA transcription28.